Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda + Lenvima vs Keytruda for untreated advanced melanoma
CTR20200368Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab, lenvatinib in melanoma, sponsored by Merck & Co.. Started Mar 2020; status: terminated.
02
Drugs
pembrolizumablenvatinib
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20200368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200368.